Preoperative acute pancreatitis and hyperenzymemia are associated with poor prognosis in patients with nonfunctional pancreatic neuroendocrine tumors

J Surg Oncol. 2023 Jun;127(7):1135-1142. doi: 10.1002/jso.27227. Epub 2023 Mar 13.

Abstract

Background: We aimed to investigate the prevalence of acute pancreatitis (AP) and hyperenzymemia as well as their clinical impact on postoperative survival outcomes in patients with pancreatic neuroendocrine tumors (PNETs).

Methods: A retrospective cohort study of 218 patients who underwent radical surgical resection for nonfunctional PNETs (NF-PNETs) was conducted. Multivariate survival analysis was performed by the Cox proportional hazard model, with results expressed as hazard ratio (HR) and 95% confidence interval (CI).

Results: Of the 151 patients who met the inclusion criteria, the incidences of preoperative AP and hyperenzymemia were 7.9% (12/152) and 23.2% (35/151), respectively. The mean recurrence-free survival (RFS, 95% CI) for patients in control, AP, and hyperenzymemia groups was 136 (127-144), 88 (74-103), and 90 (61-122) months, with a 5-year RFS rate of 86.5%, 58.3%, and 68.9%, respectively. In the multivariable-adjusted Cox hazard model that included tumor grade and lymph node status, the adjusted HR of AP and hyperenzymemia for recurrence was 2.58 (95% CI: 1.47-7.86, p = 0.008) and 2.43 (95% CI: 1.08-7.06, p = 0.040).

Conclusion: Preoperative AP and hyperenzymemia are associated with poor RFS following radical surgical resection in NF-PNETs patients.

Keywords: acute pancreatitis; amylase; lipase; pancreatic neuroendocrine tumors; prognosis.

MeSH terms

  • Acute Disease
  • Humans
  • Neuroectodermal Tumors, Primitive*
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms* / pathology
  • Pancreatitis* / epidemiology
  • Prognosis
  • Retrospective Studies

Supplementary concepts

  • Non functioning pancreatic endocrine tumor